Key Highlights

• Net Revenue increased 4.1% year-over-year to $1,493.5 million in Q3 2026.

• GAAP Net Income rose 10.8% to $57.4 million, with diluted EPS up 18.8% to $0.38.

• Adjusted EBITDA grew 4.3% to $124.6 million, while adjusted diluted EPS increased 8.9% to $0.49.

• The company has entered a definitive Merger agreement to be acquired by Clayton, Dubilier & Rice and McKesson Corporation.

Option Care Health, Inc.(NASDAQ:OPCH), the largest independent provider of home and alternate site infusion services in the United States, reported its third-quarter 2026 financial results against the backdrop of a pending acquisition. The company posted modest but steady growth across key financial metrics, though it has withdrawn forward guidance in light of the expected transaction.

Revenue and Earnings Continue Upward Trend

Net revenue for the three months ended September 30, 2026, totaled $1,493.5 million, a 4.1% increase compared to the prior-year period. The growth reflected the continued expansion of the company's nationwide infusion services network, which serves patients with both acute and chronic conditions across all 50 states.

GAAP net income reached $57.4 million, up 10.8% from the year-ago quarter, translating to Diluted Earnings per Share of $0.38, an 18.8% improvement. On an adjusted basis, EBITDA grew 4.3% to $124.6 million, while adjusted diluted EPS increased 8.9% to $0.49. Operating Cash Flow generation remained notable at $114.7 million for the quarter.

The financial results suggest the company's operations have continued to perform in line with recent trends, even as management attention is divided by the pending merger process.

Pending Acquisition by CD&R and McKesson

Option Care Health has entered into a definitive merger agreement under which it will be acquired by Clayton, Dubilier & Rice (CD&R), a Private Equity firm, and McKesson Corporation, a healthcare distribution and technology company. In connection with the pending acquisition, the company did not host an earnings conference call for the quarter and has withdrawn its previously disclosed financial guidance.

The transaction, once completed, would take Option Care Health private. The Withdrawal of guidance is a standard practice for companies in the process of being acquired, as forward-looking projections can conflict with the regulatory and legal requirements surrounding such deals.

Operational Scale and Market Position

With more than 8,000 team members, including over 5,000 clinicians, Option Care Health operates as the nation's largest independent home and alternate site infusion services provider. The company's services span a range of therapies for acute and chronic conditions, delivered through a national network that reaches patients in every state.

The Q3 results underscore the operational consistency that likely attracted CD&R and McKesson to the business. The combination of recurring healthcare demand, a nationwide clinical infrastructure, and improving profitability metrics makes home infusion a segment with predictable revenue characteristics.

The Bottom Line

Option Care Health's Q3 2026 results demonstrate continued operational momentum, with revenue, earnings, and cash flow all moving in a positive direction. However, the company's near-term narrative is dominated by its pending acquisition rather than its standalone financial trajectory. With guidance withdrawn and no conference call held, shareholders are left to monitor the merger process for closing timelines and regulatory approvals. The transaction represents a significant chapter for the company as it moves from the public markets into private ownership under two established healthcare and Investment entities.